EXPLORING THE THERAPEUTIC POTENTIAL OF XANTHINE OXIDASE INHIBITORS IN CORONARY ARTERY DISEASE - allopurinol in CAD

Phase 1

• Conditions: Ishaemic heart disease; Angina, acute myocardial infarction

• Registration Number: EUCTR2005-003081-42-GB
• Lead Sponsor: niversity of DUndee

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-07-25
• Last Update Posted: 3 April 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

1) Stable angina pectoris with no heart failure
2) Acute MI
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1 and 2)
Renal failure. Creatinine > 190mM/l
Contraindication to allopurinol (as per BNF)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: 1) To assess if allopurinol improves endothelial function in angina patients.<br>2) To assess if allopurinol improves post MI LV remodelling in post MI patients;Secondary Objective: ;Primary end point(s): 1) Change in endothelial function as assessed by strain gauge plethysmography and infusion of vasoactive substances and also USS assessment of FMD, compared to placebo<br>2) Change in LV remodelling assessed by MRI compared to placebo